ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia

Summary

To assess whether ATG Combined With Cyclophosphamide and cord blood infusion can accelerate hematopoietic reconstruction in severe aplastic anemia patients and improve clinical curative effect and safety

Conditions

• Aplastic Anemia

Interventions

DRUG

Rabbit ATG, (Genzyme)

ATG is an infusion of rabbit-derived antibodies against human T cells, which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia

DRUG

Cy

Cyclophosphamide is a medication mainly used in chemotherapy. It is an alkylating agent of the nitrogen mustard type

DRUG

CsA

CsA is an immunosuppressant drug widely used in organ transplantation to prevent rejection. It reduces the activity of the immune system by interfering with the activity and growth of T cells

BIOLOGICAL

Cord blood

Cord blood is blood that remains in the placenta and in the attached umbilical cord after childbirth. Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and genetic disorders

Sponsors & Collaborators

• Shandong University of Traditional Chinese Medicine

  collaborator OTHER

• Jining Medical University

  collaborator OTHER

• Weifang Medical University

  collaborator OTHER

• Guangzhou First People's Hospital

  collaborator OTHER

• Harbin Hematology and Oncology Institute

  collaborator OTHER

• Jining First People's Hospital

  collaborator OTHER

• JIANGXI Provincal People's Hospital

  collaborator UNKNOWN

• Jinhua Central Hospital

  collaborator OTHER

• Linyi People's Hospital

  collaborator OTHER

• Shandong Cord Blood Bank

  collaborator UNKNOWN

• Qingdao Hiser Medical Group

  collaborator OTHER

• Qingdao University

  collaborator OTHER

• Taian City Central Hospital

  collaborator OTHER

• Yantai Yuhuangding Hospital

  collaborator OTHER

• Yishui Central Hospital of LINYI

  collaborator UNKNOWN

• Institute of Hematology & Blood Diseases Hospital, China

  collaborator OTHER

• Shengjing Hospital

  collaborator OTHER

• Jinan Military General Hospital

  lead OTHER

Principal Investigators

• Fang Zhou, MD · The General Hospital Of Jinan Military Command

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

1 Year

Max Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-02-28

Primary Completion

2018-12-31

Completion

2019-07-31

Countries

• China

Study Locations